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Representing Diversity in the Dish:
Using Patient-Derived in VitroModels
to Recreate the Heterogeneity of
Neurological Disease
Layla T. Ghaffari ‡, Alexander Starr ‡, Andrew T. Nelson † and Rita Sattler*
Department of Neurobiology, Barrow Neurological Institute, Dignity Health—St. Joseph’s Hospital and Medical Center,
Phoenix, AZ, United States
Neurological diseases, including dementias such as Alzheimer’s disease (AD) and
fronto-temporal dementia (FTD) and degenerative motor neuron diseases such as
amyotrophic lateral sclerosis (ALS), are responsible for an increasing fraction of worldwide
fatalities. Researching these heterogeneous diseases requires models that endogenously
express the full array of genetic and epigenetic factors which may influence disease
development in both familial and sporadic patients. Here, we discuss the two primary
methods of developing patient-derived neurons and glia to model neurodegenerative
disease: reprogramming somatic cells into induced pluripotent stem cells (iPSCs), which
are differentiated into neurons or glial cells, or directly converting (DC) somatic cells into
neurons (iNeurons) or glial cells. Distinct differentiation techniques for both models result
in a variety of neuronal and glial cell types, which have been successful in displaying
unique hallmarks of a variety of neurological diseases. Yield, length of differentiation, ease
of genetic manipulation, expression of cell-specific markers, and recapitulation of disease
pathogenesis are presented as determining factors in how these methods may be used
separately or together to ascertain mechanisms of disease and identify therapeutics for
distinct patient populations or for specific individuals in personalized medicine projects.
Keywords: IPSC, iNeuron, ALS, FTD, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease
INTRODUCTION
Despite recent, rapid advancement in our understanding of biology and genetics, neurological
disease remains a persistent and fatal threat to human health. The World Health Organization
(WHO) estimates that the fraction of worldwide deaths attributable to neurological conditions
increased 89% from 2000 to 2015 (WHO, 2017). Alzheimer’s disease (AD) and other dementias
make up the vast majority of these fatalities, but Parkinson’s disease (PD), epilepsy, Huntington’s
disease (HD), and motor neuron diseases such as amyotrophic lateral sclerosis (ALS) are each
responsible for tens of thousands of deaths per year. The variety of symptoms and heterogeneity of
affected individuals make diseases of the central nervous system (CNS) difficult to diagnose, study,
and treat (Kim and Jeon, 2016; Van Cauwenberghe et al., 2016; Van Damme et al., 2017).
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Staining of post-mortem tissue remains the only means of
officially diagnosing several neurological diseases, and studying
the mechanisms behind defining proteinopathies is difficult
in this static state. The postmitotic nature of neurons and
difficulty of tissue access make biopsies of the CNS infeasible,
and the blood-brain barrier isolates many biochemical signals of
disease progression from peripheral biofluids. Thus, in order to
properly study pre-symptomatic disease or disease progression
mechanisms in patients, we must rely on human in vitromodels.
For genetically inherited disease, where a specific causal
mutation has been identified, cellular models of disease can
be created by genetic manipulations (overexpression, siRNA
knockout, CRISPR/Cas9 knock-in, or knock-out) of cells lines
or primary rodent cell cultures. Alternatively, primary rodent
cell cultures can be generated from existing animal models
of disease (e.g., mutant SOD1 mouse model of ALS, R2/6
mouse model of Huntington’s disease). These approaches do
come with limitations. For example, overexpression models can
simultaneously mask subtle disease phenotypes while falsely
exaggerating or creating entirely non-biological pathology.
While these models may be used for early studies into
disease mechanisms, true biological representation, especially
for potential therapeutic development, requires endogenous
expression of known genetic mutations and their genetic
interactors, which emphasizes the need for patient-derived
models.
Patient-derived models become even more necessary for
studying sporadic disease, as there is no way of definitively
recapitulating the disease in a non-diseased organism.
The genetic and epigenetic heterogeneity of sporadic
patients may make specific causative mutations statistically
undetectable, or a confluence of small changes may be required
to cause disease phenotypes. Such complexity would be
impossible to recapitulate through genetic manipulation of
a non-diseased cell, even if the full spectrum of contributory
expression was identified. Since sporadic patients make
up the majority of patients in diseases such as ALS,
Frontotemporal Dementia (FTD), and AD (Kim and Jeon,
2016; Van Cauwenberghe et al., 2016; Van Damme et al.,
2017), sporadic patient-derived cells offer the most widely
applicable tool for studies of disease mechanisms and therapeutic
screens.
Two primary methods for generating patient-derived cells
have emerged. Somatic cells can be reprogrammed into induced
pluripotent stem cells (iPSCs) and then differentiated into the
desired cell type or directly converted (DC) into the desired cell
type (Figure 1). Each method has been expanded over the last
decade for differentiation into a wide variety of CNS cells used
to study and treat neurological disease. Here, we review how
these models have developed over the last 10 years, the methods
used to differentiate them, the specific cell types those methods
produce, and how disease has been studied in these models. We
also highlight how human culture models are providing us with
new mechanistic insights that were previously unattainable with
postmortem patient tissue analysis or animal models of disease,
and discuss the current limitations of in vitro modeling of CNS
disease.
IPSC OVERVIEW
Early experiments in using stem cells to model neurons were
largely developmental and relied upon the differentiation of
embryonic stem cells (ESCs) (Thomson et al., 1998). Because
these cells were not patient-derived, they were either cultured
from mutant mouse embryos (Di Giorgio et al., 2007) or
were healthy ESCs transfected to overexpress known mutants
(Karumbayaram et al., 2009). These models encounter the same
setbacks as all over-expressions, and thus offer little improvement
over simpler models. Recently, preimplantation genetic diagnosis
(PGD) has offered an opportunity for ESCs to be generated from
embryos known to carry disease causing mutations, namely the
hexanucleotide expansion of C9orf72 (C9) (Cohen-Hadad et al.,
2016). Methylation analysis of motor neurons differentiated from
these ESCs compared to adult C9 patient-derived iPSCs revealed
hypermethylation of the iPSCs, which would suggest that ESCs
provide a better representation of patient epigenetics. However,
ethical concerns, the limited availability of endogenouslymutated
ESCs, and their inability to be used tomodel sporadic disease calls
for the ability to generate human-derived in vitro models from
adult patients. Experiments which showed that ESC fusion could
confer pluripotency to fibroblasts suggested that certain cellular
products might induce pluripotency even in an adult somatic cell
(Cowan et al., 2005).
Since the initial, groundbreaking discovery of four
transcription factors (Oct3/4, Sox2, c-Myc, and Klf4) capable of
converting adult mouse (Takahashi and Yamanaka, 2006) and
human (Yu et al., 2007) fibroblasts into pluripotent stem cells, a
number of new methods for reprogramming somatic cells have
been developed, including the use of various viral and chemical
transfection methods to express optimized pluripotency factors.
iPSCs can be generated from a wide variety of somatic cells,
including skin, peripheral blood mononuclear cells, and hair,
which enables non- or minimally-invasive collection of patient
samples to generate models of their disease (Egusa et al., 2010).
IPSC DIFFERENTIATION METHODS
Prior to the choice of which specific neural cell to generate,
the basic method of differentiation must be chosen. Many
protocols rely on the addition of small molecules and growth
factors to first induce embryoid bodies followed by neural
rosettes (Elkabetz et al., 2008), or procede directly from iPSCs
to neuroprogenitor cells (NPCs) via dual-SMAD signaling
inhibition (Chambers et al., 2009). NPCs can be maintained and
further differentiated and matured using growth factors. NPCs
can be infinitely expanded, frozen down, and thawed to provide a
mid-differentiation starting point, which reduces derivation time
by∼30% (Brafman, 2015).
Some differentiation protocols combine small molecules and
growth factors with transfection of lineage-specific transcription
factors, in a manner similar to direct conversion. For example,
Wen et al. used transcription factors established by Son et al.
for direct conversion to generate iPSC induced motor neurons
for the study of repeat associated non-ATG (RAN) translated
dipeptide repeat proteins (DPRs) in C9 ALS (Son et al., 2011;
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FIGURE 1 | Illustration of the generation and application of patient-derived models. Patient cells are used to generate iPSC or DC-based in vitro models of familial or
sporadic disease. These models are studied to elucidate disease-contributing mechanisms and screen preclinical therapeutics, which can be translated into
treatments for donor patient populations.
Wen et al., 2014). Other groups have reported that transcription
factors may be used to more quickly generate very pure cultures
of dopaminergic and GABAergic neurons (Theka et al., 2013;
Yang et al., 2017). Neural progenitor cells (NPCs) have been
derived using only small molecules (Reinhardt et al., 2013), and Li
et al. discovered that microRNA 199a could induce angiogenesis
in iPSCs, which may indicate that small-molecule only and
microRNA based differentiation protocols, which have been used
more widely in direct conversion, could be developed for iPSCs
(Li Z. et al., 2015).
Another differentiation alternative attempts to recreate the
physics of the biological environment by differentiating iPSCs
in structured organoids. Unique basal hydrogels, custom culture
chambers, and physical agitation can be used to encourage
iPSCs to differentiate into a specific three-dimensional structure
(Lindborg et al., 2016). This may lead to greater representation
of brain-layer formation, which may improve cell maturity,
stimulate expression of disease phenotypes, and provide a more
accurate model for drug screens (Raja et al., 2016). In addition,
organoids can provide a method of modeling diseases which are
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difficult to recreate in animal models, such as microencephaly
(Lancaster et al., 2013).
IPSC DIFFERENTIATED CELL TYPES
Human iPSCs have been successfully differentiated into a
number of disease-relevant cell types, as verified by morphology,
gene expression profiles, and cell-specific protein expression.
Many differentiation protocols begin with the development of
(NPCs). These have been used primarily for the development of
therapeutic neuron replacement (Nicaise et al., 2017). Similarly,
oligodendrocyte precursors have been used to drive implanted
cells to an oligodendrocyte fate for remyelination therapies
(Douvaras et al., 2014; Kawabata et al., 2016). Differentiation
beyond precursors yields neurons and glia with varying
efficiencies and purity. Variations in small molecule and growth
factor selection, maturation duration, and culture conditions
continue to be optimized.
iPSC Brain-Native Neuronal Subtype
Differentiation
iPSCs have been differentiated into a number of brain-native
neuronal subtypes. Cortical glutamatergic neurons can be
generated by initializing neuralization using retinoids and SMAD
inhibition. This generates cerebral cortex stem cells, which
mature over 60 days into neurons representing the cortical
layers (Shi et al., 2012). Viral expression of LMX1A in NPC
cultured on PA6 stromal cell yields dopaminergic (DA) neurons
(Sanchez-Danes et al., 2012). The combined effect of virally
expressed ASCL1, NURR1, and LMX1A can generate iPSC DA
neurons without the need for PA6 co-culture (Theka et al., 2013).
Inhibitory GABA-ergic neurons can also be derived via viral
induction of ASCL and DLX2 (Yang et al., 2017). These are but
a few examples of the wide variety of neuronal subtypes created
from iPSCs from an even wider array of protocols.
iPSC Spinal Motor Neuron Differentiation
Neurons native to the spinal cord and periphery, includingmotor
and sensory neurons, can be generated readily from iPSCs. iPSC
motor neurons (iPSCMNs) are generated by treatment with
retinoic acid and sonic hedgehog (SHH), which is required for
floor-plate differentiation (Ericson et al., 1996). iPSCMNs express
HB9, Islet-1, and ChAT, which indicate a mature cholinergic
maturation (Dimos et al., 2008). Peripheral nerves have also
been successfully modeled using iPSCs. Nociceptor precursor
cells can be generated from stem cells in 24 days, transfected
to overexpress Neurog1, and matured into capsaicin-sensitive
nociceptors to study nerve pain disorders (Boisvert et al., 2015).
iPSC Glial Differentiation
Glia can also be recreated from iPSCs, including astrocytes,
oligodendrocytes, and microglia. These can be studied as
mono-cultures or co-cultured with neurons to study non-cell
autonomous effects on disease, be they contributory or
compensatory.
Astrocytes are necessary to provide neurotrophic support
and maintain healthy synaptic conditions. Krencik et al first
reported the differentiation of iPSCs into astrocytes (Krencik
et al., 2011). The resulting cells were GFAP positive, S100B
positive, and took 180 days to differentiate, because astrocyte
differentiation occurs after neuronal differentiation (Emdad
et al., 2012). Differentiating iPSCs into neural stem cells before
astrocyte differentiation reduced the generation time to 6
weeks (Shaltouki et al., 2013). Fluorescence-activated cell sorting
(FACS) of differentiated iPSCs virally transfected to express GFP
under a GFAP promoter allows for the selection of a purely
astrocytic culture and reduces “noise” from neurons and other
glia remaining from early periods of differentiation (Zhang et al.,
2016).
In addition to the use of oligodendrocyte precursors
(OPCs) in therapeutic transplantation, mature iPSC-derived
oligodendrocytes have been generated. Early reports suggested
that iPSCs might contain some inherent factor which prevented
oligodendrocyte maturation (Tokumoto et al., 2010), however, a
low yield, high purity, three-month protocol was soon developed
(Hu et al., 2009). These mature oligodendrocytes were capable
of generating myelin sheaths. Oligodendrocyte precursors can be
matured by co-culture with dorsal root ganglion (DRG) neurons
and will myelinate them in vitro (Czepiel et al., 2011). Douvaras
et al. used a protocol similar to iPSMN differentiation, including
adherent dual SMAD inhibition and early caudalization and
ventralization, to increase OPC yield and shorten differentiation
time to 75 days (Douvaras et al., 2014).
Microglia derive from macrophages but do not gain certain
distinct features until they develop in concert with the nervous
system. Early attempts to generate microglia from iPSCs resulted
in cells called microglia-like macrophages, and while they did
not express typical microglial morphology, they were positive for
IBA1, CD45 and CD11b (Muffat et al., 2016). When microglia-
like macrophages were co-cultured with iPSCNs, they exhibited
a more mature microglial morphology and phagocytic behavior
(Haenseler et al., 2017a). Recently, Douvaras et al. reported a
method to develop mature, ramifying microglia without co-
culturing (Douvaras et al., 2017).
iPSC Differentiation into Neural-Interfacing
Cell Types
Non-neuronal cells relevant to neurological disease have also
been derived. iPSCs can be differentiated into myoblasts,
which form contracting, electrically and chemically responsive
myotubes that are capable of forming neuromuscular junctions
(NMJs) (Demestre et al., 2015). Additionally, endothelial cells
can be generated to model the blood-brain-barrier, which is
suggested to be compromised in neurodegeneration (Lippmann
et al., 2012).
With the ability to differentiate into the full complement
of neurons, glia, and neural-interfacing cells, iPSCs provide a
powerful model for the study of disease in individual cells, in
co-culture, and in three-dimensional reconstructions of complex
tissues. Many examples of subtype-specific differentiation
methods focus on the expression of specific marker proteins.
While this is an important indicator of an individual cell type,
more parameters can and should be considered when evaluating
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differentiation protocols. For example, positive expression of
marker proteins should be correlated with the lack of expression
of specific marker proteins of similar, yet distinct, cell types, e.g.,
cortical forebrain neurons should lackmarkers of motor neurons.
In addition, gene expression profiles should be compared to
data from either primary murine cultures of the same cell type
or isolated cell types from postmortem brain tissues. Similarly,
morphology and electrophysiological activity should be included
in the cell characterization. This will increase confidence in
claims of cell-type specificity and also provide more experimental
readouts to use as standards for maintaining consistent models
across multiple rounds of differentiation.
Additional steps may be employed to reduce differentiation
variability and to ensure disease relevance of observed deficits.
While the use of multiple disease and control cell lines controls
for the variability between individual human subjects, multiple
differentiations of the same cell line accounts for variability
between differentiations. In addition, CRISPR-Cas9 mediated
gene editing allows for the correction of disease-causing
mutations (Cong et al., 2013). This provides the possibility
of creating isogenic control iPSC lines, which genetically
and epigenetically match patient derived lines, except for the
corrected mutation. If this correction alleviates deficits, it
supports the association between the gene mutation-dependent
phenotypes and actual disease pathology. This can be
strengthened further by using the same technique to introduce
known mutations in healthy control iPSCs, creating a positive
control. Unfortunately, isogenic controls cannot be created to
study sporadic disease which, as mentioned above, represents the
majority population of most neurodegenerative diseases.
IPSC MODELS OF DISEASE
Amyotrophic Lateral
Sclerosis/Frontotemporal Dementia
iPSCs have been used extensively to model neurological disease
(Figure 2). ALS, a fatal motor neuron disease, and FTD,
a neurodegenerative dementia, appear to exist on a genetic
spectrum of disease, with several shared genetic causes and
identifying pathologies. It is in this spectrum that the widest
variety of iPSC modeling has been employed. iPSCMNs are
the most widely used, and have been shown to demonstrate
the specific pathology and physiology of ALS subtypes. Dimos
et al. were the first to report the generation of iPSCMNs
from an ALS patient that expressed the motor neuron-specific
transcription factors HB9 and Islet 1 (Dimos et al., 2008). It
was not until four years later that actual disease phenotypes
were first shown in TDP-43 ALS patient-derivedmotor neurons.
Egawa and colleagues differentiated iPSCMNs from three
ALS patients carrying three distinct TDP-43 mutations and
showed that, among other deficits, the diseased motor neurons
exhibited hallmark TDP-43 aggregates similar to those found
in postmortem ALS brain tissues (Egawa et al., 2012). The
authors were able to rescue these phenotypes with a histone
acetyltransferase inhibitor, providing first evidence that patient-
derived iPSCMN culturemodels could be used for drug screening
purposes. iPSC modeling of FTD soon followed when Almeida
and colleagues generated iPSC neurons and microglial cells
from FTD patients carrying a mutation in progranulin (PGRN)
(Almeida et al., 2012). The differentiated human cells confirmed
the presence of PGRN haploinsufficiency, in addition to aiding
in the new discovery of mutant PGRN-specific deficits of certain
protein kinase pathways. When the C9orf72 hexanucleotide
expansion was discovered as the most common shared mutation
in ALS/FTD disease spectrum in 2011(DeJesus-Hernandez et al.,
2011; Renton et al., 2011), the fastest way to study disease
mechanisms was via iPSCs, as the generation of the repeat
expansion in mouse models proved to be difficult. Several
laboratories shortly thereafter provided the first evidence of
the three major disease mechanisms of mutant C9orf72 using
iPSC neurons: haploinsuffiency, RNA foci formation, and repeat-
associated non-ATG (RAN) translation (Almeida et al., 2013;
Donnelly et al., 2013; Lagier-Tourenne et al., 2013; Sareen
et al., 2013). These studies also revealed disease-mediated
aberrant gene expression and neuronal function in patient
iPSCs. Numerous follow up studies examining both neuronal
and glial iPSC culture models have since been used to further
investigate how mutant C9orf72 leads to neuronal degeneration,
ranging from studies on nucleocytoplasmic trafficking deficits
(Freibaum et al., 2015; Zhang et al., 2015; Lopez-Gonzalez
et al., 2016; Westergard et al., 2016) to the toxic potential
of RAN dipeptides, as recently reviewed (Selvaraj et al.,
2017).
Other familial ALS mutation phenotypes, such as valosin-
containing protein (VCP) (Hall et al., 2017), TAR DNA-binding
protein 43 (TDP-43) (Serio et al., 2013; Barmada et al., 2014), and
superoxide dismutase (SOD1) (Bhinge et al., 2017), have been
recapitulated in iPSCs showing characteristic proteinopathies,
and endoplasmic reticulum (ER) and oxidative stress. To
determine which disease pathologies in the model are caused
primarily by the mutation, isogenic corrections of known genetic
causes, such as SOD1, have been generated, and were shown to
successfully rescue the mutant phenotypes, such as previously
described hyperexcitability in SOD1 mutant iPSCMNs (Wainger
et al., 2014; Bhinge et al., 2017).
Importantly, considering sporadic disease represents 90%
of ALS patients, sporadic iPSCs have also been differentiated
into neurons and were shown to exhibit TDP-43 pathology
(Burkhardt et al., 2013; Qian et al., 2017). Furthermore, gene
expression profiling of sporadic ALS iPSCMNs suggested deficits
in mitochondrial function (Alves et al., 2015). More studies
are required to better understand the pathogenesis of sporadic
disease, and human cell culture models are currently the only way
to gain insight into what triggers and propagates sporadic ALS
and FTD.
Limited studies have addressed the role of glial cells in
ALS/FTD, although both ALS and FTD patient-derived iPSC
astrocytes have been employed to study the non-cell autonomous
mechanisms of neurodegeneration. Interestingly, while studies
using SOD1 mutant mouse models and primary cultures
generated from these mice unequivocally demonstrated that
mutant astrocytes trigger motor neuron degeneration, iPSC
astrocytes differentiated from ALS patients carrying a TDP-43
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FIGURE 2 | Examples of patient-derived in vitro models of neurological disease. Select examples of how patient-derived iPSC and DC neurons, astrocytes, and
microglia have been used to model ALS/FTD, AD, HD, and PD. Numbers correspond to the following references: 1. Donnelly et al., 2013; 2. Wang et al., 2014; 3.
Burkhardt et al., 2013; 4. Wen et al., 2014; 5. Hall et al., 2017; 6. Serio et al., 2013; 7. Barmada et al., 2014; 8. Qian et al., 2017; 9. Almeida et al., 2012; 10. Liu et al.,
2016; 11. Lim et al., 2016; 12. Son et al., 2011; 13. Su et al., 2014; 14. Meyer et al., 2014; 15. Yagi et al., 2011; 16. Kondo et al., 2013; 17. Muratore et al., 2014; 18.
Balez et al., 2016; 19. Sproul et al., 2014; 20. Jones et al., 2017; 21. Zhao et al., 2017; 22. Abud et al., 2017; 23. Hu et al., 2015; 24. Hou et al., 2017; 25. Nekrasov
et al., 2016; 26. Grima et al., 2017; 27. Mattis et al., 2015; 28. Juopperi et al., 2012; 29. Hsiao et al., 2014; 30. Hsiao et al., 2015; 31. Liu et al., 2013; 32. Devine
et al., 2011; 33. Imaizumi et al., 2012; 34. Seibler et al., 2011; 35. Haenseler et al., 2017b; 36. Puschmann et al., 2017.
mutation, while exhibiting TDP-43 mislocalization themselves,
did not affect motor neuron survival in a co-culture model (Serio
et al., 2013). On the other hand, iPSC astrocyte-conditioned
media derived from C9orf72 patients leads to impairments of
iPSC motor neuron autophagy (Madill et al., 2017). Similarly,
iPSC astrocytes from mutant VCP patients affect motor neuron
survival in vitro (Hall et al., 2017). In addition, transplanting
sporadic ALS iPSCs into the spinal cord of WT mice resulted
in differentiation into astrocytes and triggered a loss of neurons
in the spinal cord, with accompanying movement deficits (Qian
et al., 2017).
Even fewer studies to date have generated and characterized
iPSC-derived oligodendrocytes. Ferraiuolo and colleagues used
both sporadic and fALS patient-derived oligodendrocytes to
show that, similar to astrocytes, diseased oligodendrocytes
affect motor neuron survival (Ferraiuolo et al., 2016). At the
same time, Livesey and colleagues studied the maturation and
electrophysiological properties of C9orf72 patient-derived iPSC
oligodendrocytes and did not observe any obvious impairments
or alterations of these cells when grown in mono-cultures
(Livesey et al., 2016).
The only study describing iPSC microglial cells from
ALS or FTD patients was reported by Almeida et al. who
showed that PGRN FTD patient microglial cells exhibit
progranulin haploinsufficiency, but do not show the deficits in
serine/threonine kinase S6K2 observed in iPSC neurons from the
same patients (Almeida et al., 2012).
Alzheimer’s Disease
The most common dementia, Alzheimer’s disease (AD), has been
examined extensively in patient-derived iPSCs, and these studies
been thoroughly reviewed (Devineni et al., 2016; Arber et al.,
2017; Robbins and Price, 2017; Tong et al., 2017). One of the first
reports using patient-derived iPSC neurons to study mechanisms
of AD examined the pathogenesis of familial Presenilin 1 (PS1)
and Presenilin 2 (PS2) (Yagi et al., 2011). The mutant iPSC
neurons exhibited increased amyloid β 42 secretion, which was
inhibited by a γ-secretase inhibitor. This study was followed
by a report from Israel and colleagues who found an increase
in Aβ and phosphorylated tau (p-tau) in familial amyloid-β
precursor protein (APP) duplication (APP(Dp)) and sporadic
iPSC cortical neurons (Israel et al., 2012). Treating patient
neurons with β-secretase inhibitor, but not γ-secretase inhibitors,
significantly reduced the documented disease phenotypes in the
cells, providing new knowledge on the mechanisms of APP
pathogenesis.
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These early studies were followed by reports using both
familial and sporadic AD patient iPSCs differentiated into
cortical neurons or, to a limited degree, glial cells to better
understand mechanisms of neurodegeneration in AD and for
novel therapeutic target investigation. For example (Duan et al.,
2014), used sporadic AD patient iPSCs with ApoE3/E4 genotypes
and reported not only an increased ratio of Aβ42/40 and
responsiveness to γ-secretase inhibitors, but also increased
susceptibility to glutamate toxicity with a concomitant increase
in free intracellular calcium levels, suggesting that actual
neuroprotection could be examined using these patient-derived
neurons. Similarly, iPSCs from AD patients carrying an APP
mutation (V717I) showed increased expression levels of APP
and Aβ, in addition to aberrant β and γ secretase cleavage
of APP and increased levels of total and phosphorylated tau
(Muratore et al., 2014). Interestingly, the authors were able to
show that treatment with specific Aβ antibodies early during
the differentiation process rescued the mutant APP phenotypes.
This new paradigm of testing drugs in patient-derived cells was
strengthened by a study in which apigenin has been tested as a
potential anti-inflammatory therapeutic in AD patient-derived
neurons co-cultured with activated murine microglial cells. The
treatment was successful in reversing morphological deficiencies,
reducing hyper-excitability, and protecting against apoptosis
(Balez et al., 2016).
Sproul and colleagues studied iPSC derived neural precursor
cells (NPC) to understand whether, even at a pre-neuronal
stage of development, human cells show AD phenotypes (Sproul
et al., 2014). Differentiating iPSCs from mutant PS1 patients into
NPCs, the authors observed an increased Aβ42/40 ratio and an
aberrant gene expression profile after transcriptome analysis. A
select number of gene aberrations were confirmed to be similarly
altered in postmortem AD brain tissues. Similar findings were
confirmed in PS1 patient iPSC neurons (Mahairaki et al., 2014).
Interestingly, generating isogenic iPSC lines using TALENs (TAL
Effector Nucleases) technology to insert PS11 E9 mutations in
otherwise healthy control patient lines lead to the discovery that
this mutation represents a toxic gain of function mutation that
impairs PS1-dependent γ secretase activity, but not unrelated γ
secretase functions (Woodruff et al., 2013).
Few studies thus far have used patient-derived iPSC astrocytes
to model Alzheimer’s disease. Kondo et al showed that iPSC
astrocytes from sporadic AD patients and patients with an
(APP)-E693delta mutation displayed ER and oxidative stress,
which was alleviated with treatment of docosahexaenoic acid
(DHA) (Kondo et al., 2013). A more recent study showed
that iPSC astrocytes from familial and sporadic AD patients
display significant morphological phenotypes with an overall
atrophic profile andmislocalization of astroglial marker proteins,
including S100B (Jones et al., 2017). IPSCs astrocytes from
normal individuals with APOE ε4/ε4 genotypes were less
effective in promoting neuronal survival and synaptogenesis
when compared to iPSC astrocytes from normal individuals
with APOE ε3/ε3 genotypes (Zhao et al., 2017), illustrating that
patient-derived culture models could aid in exploring the role
of individual apoE isoforms in AD disease pathogenesis. Finally,
iPSC astrocytes differentiated from patients carrying the PSEN1
delta E9 mutation exhibited typical AD pathology—increased β
amyloid, altered cytokine release, defective calcium homeostasis,
increased oxidative stress and reduced lactate secretion (Oksanen
et al., 2017). None of these phenotypes were present in healthy
control or gene-corrected isogenic iPSC astrocytes.
Similar to ALS above, only one study to date has used
patient-derived microglial cell to study AD disease mechanisms.
Abud and colleagues generated iPSC microglial-like cells and
showed altered gene expression in response to Aβ fibrils and
aberrant phagocytic activity when exposed to brain-derived
tau oligomers (Abud et al., 2017). Further work is required
to determine whether the observed AD iPSC-derived glial
phenotypes contribute to the neuronal disease pathogenesis in a
non-cell autonomous manner.
To overcome the observed inability of 2 dimensional iPSC
neuron cell culture models to generate extracellular protein
aggregations, the AD field has quickly tried to model AD in 3
dimensional (3D) human cell culture systems (reviewed by and
Choi et al., 2016; Lee et al., 2017). One of the first published
studies using 3D iPSC differentiated neuron cultures showed that
only in the 3D environment did the AD neurons display p21-
activated kinase-mediated sensing of Aβ oligomers, in addition
to the presence of F-actin associated protein phenotypes (Zhang
et al., 2014). Choi and colleagues developed a 3D iPSC neuron
culture model from familial AD patients (mutant APP and
mutant presenilin), which, for the first time, represented a disease
model that displayed hallmarks of AD pathology: extracellular
deposition of amyloid-β, including amyloid-β plaques, and
aggregates of phosphorylated tau, as well as filamentous tau (Choi
et al., 2014; Kim et al., 2015). More recent studies have applied
the 3D culture model to generate high throughput models for
drug screening against tau aggregation (Medda et al., 2016),
or to compare efficacy of drug candidates (β or γ secretase
inhibitors) in 2D vs. 3D culture systems (Lee et al., 2016).
Finally, the generation of brain organoids, initially developed
to model human brain development (Lancaster et al., 2013),
has been adopted to study mechanisms of AD as well. Raja
and colleagues reported that brain organoids from familial AD
patients recapitulate AD disease phenotypes and pathologies
including amyloid aggregation, hyperphosphorylated tau, and
endosome abnormalities, all of which were reduced by treatment
with secretase inhibitors (Raja et al., 2016).
Huntington’s Disease
Zhang and colleagues were the first group to characterize HD
patient-derived iPSC neuronal cells (Zhang et al., 2010). The
authors differentiated iPSCs into striatal neurons expressing cell-
specific markers such as DARPP-32. The neurons maintained
the CAG repeat expansion and showed increased susceptibility
to growth factor removal as shown by enhanced caspase
activity. The same research team also generated the first gene-
corrected isogenic cell lines, which resulted in the rescue of
disease phenotypes, including the susceptibility to cell death and
mitochondrial abnormalities (An et al., 2012). A large consortium
of Huntington’s disease researchers reported increased cell death,
sensitivity to stressors, increased glutamate toxicity, and reduced
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sporadic electrical firing in HD patient-derived iPSC striatal-
like neurons as characterized by the expression of Map2a/b
and Bcl11B (iPSC Consortium, 2012). Interestingly, the severity
of several of these phenotypes increased in proportion to
the patient’s CAG-expansion length in the HTT gene. Similar
findings were reported by Mattis and colleagues, who reported
increased cell death following BDNFwithdrawal, but also showed
that increased susceptibility to glutamate toxicity could be
blocked by NMDA and AMPA receptor inhibitors (Mattis et al.,
2015), suggesting novel therapeutic approaches for HD.
Several other potential Huntington’s disease pathways have
been identified using patient derived iPSC neurons, such as
miR196a dysregulation (Cheng et al., 2013), MAPK and Wnt
signaling (Szlachcic et al., 2015), the protective potential of
A2A adenosine receptor activation (Chiu et al., 2015), and
astrocyte-mediated cytokine-induced neuronal cell death (Hsiao
et al., 2014). CRISPR-Cas9 gene-corrected isogenic HD patient
lines showed rescue of HD phenotypes, such as deficits in
mitochondrial respiration (Xu et al., 2017). Most interestingly,
though, these isogenic lines showed that gene expression
differences between HD and healthy control iPSCs were not
present when HD lines were compared to their isogenic control,
suggesting that general differences in genetic background
could be falsely identified as transcriptomic abnormalities
triggered by the disease-causing mutation. Neskarov et al.
reported that HD iPSC neurons show increased numbers of
lysosomes/autophagosomes and exhibit increased cell death
alongside nuclear indentation (Nekrasov et al., 2016). Further
nuclear deficits, including nucleoporin aggregation and impaired
nucleo-cytoplasmic transport, have recently been demonstrated
in HD patient-derived neurons (Grima et al., 2017); similar
to what has been described in ALS (Kim and Taylor, 2017).
One of the most recent studies showed that previously reported
repression of peroxisome proliferator-activated receptor delta
(PPAR-δ)—a ligand-gated transcription factor that promotes
mitochondrial biogenesis and oxidative metabolism—in an HD
mouse model is also found in HD patient-derived iPSC neurons
(Dickey et al., 2016, 2017). Indirect activation of PPARγ via the
small molecule compounds bexarotene or KD3010 significantly
rescued impaired oxidative metabolism in HD neurons.
There have been few reports of iPSC differentiations into
non-neuronal cells for HD. Huntington’s iPSC astrocytes were
shown to express higher levels of vascular endothelial growth
factor-A (VEGF-A) (Hsiao et al., 2015) and formed electron-
clear vacuoles, which increased during the differentiation period
but appeared independently of cellular stressors (Juopperi et al.,
2012). To date, patient derived microglia and oligodendrocytes
have not been studied in Huntington’s disease, but differentiation
of HD iPSCs into brain microvascular endothelial cells revealed
abnormalities in angiogenesis and blood brain barrier properties
(Lim et al., 2017).
In summary, the use of patient-derived iPSC cultures in
HD has provided new insight regarding disease pathogenesis
and also provided a novel model to perform pre-clinical
drug discovery (Tousley and Kegel-Gleason, 2016). A potential
additional application of these patient-derived cells lies in
the transplantation of stem cells or their derivatives to
replace diseased or lost neurons. While not discussed in this
review, numerous efforts have been made toward successful
transplantation of cells at the iPSC stage or the neural precursor
stage in rodents with the hope to create a therapeutic path toward
HD patient transplantations (Golas and Sander, 2016; Connor,
2017; Choi et al., 2018).
Parkinson’s Disease
Parkinson’s disease (PD) has been extensively modeled using
patient-derived iPSCs (Cobb et al., 2017). PD is modeled chiefly
by the differentiation of iPSCs into dopaminergic (DA) neurons.
Park et al. created the first Parkinson’s disease iPSC line, together
with other neurodegenerative disease lines (Park et al., 2008).
Patient-derived DA neurons exhibit the typical pathology of PD:
the presence of Lewy bodies and their main component, α-
synuclein. This pathology is present in iPSC DA neurons from
patients with mutations in the SNCA gene and in patients with
mutations in leucine-rich repeat kinase 2 (LRRK2) (Devine et al.,
2011; Nguyen et al., 2011) and, rarely, in patients with mutations
in parkin (Imaizumi et al., 2012), but not in patients with a
mutation in PTEN-induced putative kinase 1 (PINK1) (Jiang
et al., 2012). This reflects the pathology as it has been observed
in postmortem patient brain tissue. Other disease phenotypes
previously observed in either mouse models or autopsy tissue
were confirmed in patient-derived familial and sporadic iPSCDA
neurons, including mitochondrial deficits and oxidative stress
(Byers et al., 2011; Cooper et al., 2012; Hsieh et al., 2016) and
lysosomal and autophagy deficits (Mazzulli et al., 2011, 2016;
Sanchez-Danes et al., 2012; Schondorf et al., 2014; Fernandes
et al., 2016).
Similar to the aforementioned neurodegenerative diseases,
researchers are now using genetically corrected patient-derived
iPSCs to study PD pathogenesis in order to reduce the potential
for general patient-to-patient genetic variability to obscure
disease-specific cellular and genetic alterations, and to pinpoint
specific disease mechanisms linked to the genetic mutation
examined, and not to potential cellular deficits arising from the
actual cell differentiation process (Soldner et al., 2011; Arias-
Fuenzalida et al., 2017; Qing et al., 2017).
Parkinson’s disease has not been studied extensively in iPSC-
derived glia; however, Haenseler et al. have recently shown
that phagocytosis is impaired in SNCA triplication microglia
(Haenseler et al., 2017b).
Neuroinflammation and Neuropsychiatric
Diseases
Modeling disease with iPSCs extends beyond neurodegeneration.
Although much research in de-myelinating disease, such as
multiple sclerosis (MS), focuses on differentiating healthy
oligodendrocyte precursors for transplantation replacement
therapy (Kawabata et al., 2016; Sato et al., 2017), MS patient-
derived iPSCs have been differentiated into neurons (Song et al.,
2012), astrocytes (Song et al., 2012), oligodendrocyte precursors
(Nicaise et al., 2017), and oligodendrocytes (Song et al., 2012;
Douvaras et al., 2014). The only differences so far identified are
an inability of MS iPSCNs to fire spontaneous action potentials
(Song et al., 2012), and reduced neuroprotection by MS iPSC
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oligodendrocyte precursors (Nicaise et al., 2017). Microglia,
which have been sparingly used to model neurological disease,
have also been used to model Rhett syndrome (Muffat et al.,
2016). The use of iPSCs to model neuropsychiatric disorders is
expanding rapidly, as reviewed by Ho et al. (2015).
Reprogrammed patient-derived cells have been used to model
sporadic and familial neurodegenerative, neurodevelopmental,
and neuropsychiatric disease. Much early work using iPSCs
to study neurological disease focused on validating previously-
observed phenotypes from animal models and postmortem
autopsy tissues. Now that the ability of iPSC-derived CNS
models to recreate disease pathology has been established, more
recent studies are beginning to use iPSCs to tease out disease
mechanisms and screen for pre-clinical therapeutics. These
efforts are supported by continuing improvements in cell type-
specific differentiation methods, the expansion of co-culture and
3D culture models, and the generation of genetically corrected
isogenic patient lines to account for the diversity of patients’
intrinsic genetic backgrounds.
Despite the advantages and advancements of patient-derived
iPSCs, concerns about differentiation time, culture specificity
and purity, teratoma formation in transplantation, and, most
importantly, the difficulty for rejuvenated cells to model aging
diseases has led to the development of a complimentary
methodology: lineage-specific direct conversion of patient-
derived somatic cells.
DIRECT CONVERSION OVERVIEW
One distinct advantage of direct lineage conversion, also known
as transdifferentiation, is that there is no reprogramming
step. The epigenetic identity of the starting cells remains
after conversion, as opposed to the hypermethylation observed
when somatic cells are rejuvenated into iPSCs (Cohen-Hadad
et al., 2016). This retains “cellular memories.” Most conversion
protocols feature mesoderm to ectoderm conversions—meaning
fibroblasts to neurons. Due to the infancy of this field, the
definition of an induced neuron (iN) has many meanings (Yang
et al., 2011). Direct conversion can occur from fibroblasts
(Vierbuchen et al., 2010), blood (Lee et al., 2015), urine cells
(Zhang S. Z. et al., 2016), hepatocytes (Marro et al., 2011), and
adipocyte progenitors (Yang Y. et al., 2013), which provides
a wide variety of non-invasive starting materials for modeling
patient disease.
The first report of direct lineage reprogramming by
Vierbuchen et al. (2010) used combinatorial expression of
three neural lineage-specific transcription factors—Brn2, Ascl1,
and Myt1L, known as the BAM factors—to induce neurons from
mouse fibroblasts (Vierbuchen et al., 2010). The induced neurons
(hereafter called iNeurons or iNs) that result from this method
express pan-neuronal markers including Tuj1, NeuN, MAP2,
and synapsin. These iNs also fire induced and spontaneous
action potentials and form functional synapses. However, the
BAM factors alone cannot convert human fetal or postnatal
fibroblasts into functional neurons. The addition of the basic
helix-loop-helix transcription factor NeuroD1 to the BAM factor
conversion protocol was found to be necessary for iNs to be
produced from human somatic cells (Pang et al., 2011).
Here, we will first describe the general methods used to
directly convert somatic cells. We then specify conversion
methods applied to the generation of neurons and glial cells,
followed by a summary on how these directly converted cells have
been studied in varying neurodegenerative diseases thus far.
DIRECT CONVERSION METHODS
There are three primary methods of directly converting human
somatic cells into CNS cells. Transcription factor overexpression,
microRNA overexpression, and small molecule treatments can,
individually or in concert, generate a variety of cell types from
the aforementioned starting materials.
Transcription Factor-Mediated Direct
Conversion
Since Pang et al. first successfully created human iNs, a number
of other groups have obtained similar results using some or all of
the BAM transcription factors (Ambasudhan et al., 2011; Caiazzo
et al., 2011; Pfisterer et al., 2011; Son et al., 2011). Furthermore,
Marro et al. used the BAM factors to convert hepatocytes into
functional neurons, providing the first proof that an endodermal
cell can be converted into an ectodermal cell (Marro et al.,
2011). Renal epithelial cells from urine can be directly converted
into neurons via lentivirus-mediated expression of BAM factors
plus NeuroD1 and c-Myc (Zhang S. Z. et al., 2016). Mitchell
et al. (2014) showed the Oct4 expression alone was enough to
generate NPCs from somatic cells. These are only a few examples
of the variety of transcription factors used to generate neurons
(Mitchell et al., 2014).
MicroRNA-Mediated Direct Conversion
Several groups have also achieved direct conversion via
microRNAs, although concomitant expression of neural lineage-
specific transcription factors is required to fully mature these iNs.
Coexpression of miR-9/9∗ and miR-124 is sufficient to directly
convert human fibroblasts into neurons (Yoo et al., 2011). While
initial conversion efficiency using these microRNAs was very low,
efficiency increased with the addition of the transcription factors
NeuroD2, Ascl1, and Myt1. Furthermore, striatal medium spiny
neurons ormotor neurons can also be generated by co-expression
of miR-9/9∗ and miR-124 in addition to the transcription factors
BCL11B (CTIP12), DLX1, DLX2, and MYT1L or ISL1 and
LHX3, respectively (Victor et al., 2014; Richner et al., 2015;
Abernathy et al., 2017). Huh et al. also showed that direct
conversion using this protocol preserves age-related epigenetic
and cellular signatures from the donor, similar to established
transcription factor-only methods (Huh et al., 2016). Primary
dermal human fibroblasts can also be converted into functional
neurons by expression of miR-124 in addition to transcription
factors Brn2 and Myt1 (Ambasudhan et al., 2011). An additional
method reported by Zhou et al. (2014) showed that depletion
of p53 by zinc finger nuclease (ZFN) technology is sufficient to
convert fibroblasts into neurons, oligodendrocytes, or astrocytes,
depending on the selection media used (Zhou et al., 2014). It has
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not yet been established whether p53 depletion generates neurons
which recapitulate disease pathology.
Similar to microRNA-mediated approaches, expression of
short interfering RNA (siRNA) inhibiting the polypyrimidine-
tract binding (PTB) protein has been shown to be sufficient for
transdifferentiation (Xue et al., 2013). The suppression of PTB
allows for expression of various neuronal genes, including the
neuron specific microRNA-124. In non-neuronal cells, the PTB
protein inhibits microRNAs which act on various components
of the RE1-silencing transcription factor complex. Relief of this
PTB-protein inhibition leads to activation of an array of neuronal
lineage-specific genes, thereby promoting neuronal induction.
Lau et al. report using a self-regulating viral vector which
expresses BAM factors and has target sequences for microRNA-
124. Once the cells have been converted into neurons, they will
express miR-124, and then downregulate the transgenes (Lau
et al., 2014). The microRNA-mediated downregulation of the
neural conversion genes allow for more complete functional
maturation in culture.
MicroRNAs, with their ability to both promote expression of
lineage specific genes and suppress expression after conversion,
offer a path to fine-tune conversion to best replicate endogenous
expression of cell-type specific genes and more accurately
recreate their effect on disease biology in the patient.
This benefit must be weighed against the fact that most
microRNAs have a variety of target genes, and overexpression
may cause unintended dysregulation of disease-relevant
genes.
Small Molecule-Mediated Direct
Conversion
In addition to transcription factors, small molecules can convert
human fibroblasts into functional neurons without the addition
of exogenous genetic factors. The resulting neurons are called
chemically induced neurons (CiNs). Small molecules have been
shown to increase efficiency of conversions when combined
with transcription factors (Ladewig et al., 2012; Liu et al., 2013;
Lee et al., 2015; Mertens et al., 2015; Shi et al., 2016). SMAD,
GSK3β, and ALK inhibitors, alongside cyclic AMP signaling
enhancers, are common betweenCiN and iPSC differentiation. In
an early study, (Ladewig et al., 2012) combined Ascl1 and Ngn2
with the small molecules SB-431542, noggin, and CHIR99021 (a
GSK3β inhibitor). Reports of purely small molecule conversions
include a combination of forskolin, isoxazole 9 (an inducer of
neural stem cell differentiation), CHIR99021 and I-BET151 (a
BET bromodomain inhibitor), which can convert fibroblasts into
functional neurons that express pan-neuronal markers (Li X.
et al., 2015), and a small molecule cocktail called VCR, consisting
of Valproic acid, CHIR99021 and Repsox, which is capable of
inducing NPCs (Cheng et al., 2014). Hu et al. expanded VCR
and generated human CiNs using the cocktail named VCRFSGY,
which consisted of Valproic acid, CHIR99021, Repsox, Forskolin,
SP600125 (a JNK inhibitor) GO6983 (a PKC inhibitor) and
Y-27632 (a ROCK inhibitor) (Hu et al., 2015). These hCiNs
showed some spontaneous electrical activity and a train of action
potentials when stimulated.
DIRECT CONVERSION CELL TYPES
Direct conversion has generated nearly as wide a variety of
CNS cell types as have stem cell differentiation approaches.
Proneural transcription factors without subtype specification
largely result in glutamatergic and GABA-ergic iNs (Vierbuchen
et al., 2010; Wang et al., 2014; Mertens et al., 2015). Success of
specific cell type generation by direct conversion techniques are
largely based on expression of cell type-specific markers, but the
question remains if the final cell type generated mimics bona
fide neuron subtypes. As in iPSC models, cell type confidence
can be increased by considering subtype-specific morphology,
gene expression, and electrophysiology in concert with marker
proteins and in comparison to individual cell types of adult
human tissue.
Direct Brain-Native Neuronal Subtype
Conversion
Induced neural progenitor cells (iNPCs) can be generated
via expression of pluripotency factors in possible combination
with small molecules (Kim et al., 2011a; Mitchell et al., 2014;
Lee et al., 2015; Hou et al., 2017). iNPCs are not post-
mitotic, and can differentiate into various neuronal subtypes,
oligodendrocytes, and astrocytes in vivo and in vitro. Pro-
neural and serotonergic neuron-specific transcription factors,
in addition to small molecules, can generate induced neurons
that have characteristics of native serotonergic neurons such
as release of serotonin, response to SSRIs, increased expression
of specific serotonergic genes, and firing of spontaneous
action potentials (Vadodaria et al., 2016; Xu et al., 2016).
Dopaminergic neurons are of particular interest due to their
clinical relevance in Parkinson’s disease. It has been shown that
induced DA neurons (iDAs) can be generated from human
fibroblasts via a combination of transcription factors (Caiazzo
et al., 2011; Kim et al., 2011b; Pfisterer et al., 2011; Liu
et al., 2012; Torper et al., 2013; Dell’Anno et al., 2014). The
resulting iDAs displayed characteristic DA uptake and release,
expressed DA neuron-specific markers, and were electrically
active.
Direct Motor Neuron Conversion
Transdifferentiation can also model nervous system disease
outside of the brain. The small molecules Forskolin and
Dorsomorphin, in addition to the transcription factors
Neurogenin2 and SOX1, can generate human induced
cholinergic neurons with mature electrophysiological properties,
motor neuron-like features, and morphology (Liu et al., 2013).
Human induced motor neurons (hiMNs), which form functional
NMJs when cultured with primary mouse skeletal myotubes, can
be generated via expression of Ngn2, SOX11, ISL1, and LHX3,
in addition to the small molecules forskolin and dorsomorphin
(Liu et al., 2016). Son et al. utilized a transcription factor-
only (BAM factors plus motor neuron-specific transcription
factors Lhx3, Hb9, and Isl1, and NeuroD1) approach to
generate functional human spinal motor neurons (Son et al.,
2011).
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Direct Sensory Neuron Conversion
Induced sensory neurons can be generated by the transient
co-expression of Brn3a with either Ngn1 or Ngn2 and
exhibit properties of endogenous sensory neurons such as
gene expression, Trk receptor expression, response to ligands,
and morphology (Blanchard et al., 2015). Nociceptive sensory
neurons with nociceptor-specific functional receptors can be
converted from fibroblasts using BAM factors in addition to Isl2,
Ngn1, and Klf7 (Wainger et al., 2015) or via OCT4 and a small
molecule cocktail which inhibits SMAD and GSK-3β signaling
(Lee et al., 2015).
Direct Glial Conversion
Direct conversion can also produce glia. The transcription factors
NFIA, NFIB, and SOX9 can convert native brain embryonic and
postnatal mouse fibroblasts into astrocytes (iAstrocytes) (Caiazzo
et al., 2015). Induced oligodendrocyte precursor cells (iOPCs)
can be generated frommouse and rat fibroblasts by direct lineage
conversion using transcription factors such as SOX10, Olig2, and
Zfp536, Nkx6.2, Egr2 (Najm et al., 2013; Yang N. et al., 2013;
Mazzara et al., 2017). These iOPCs can differentiate in vivo and
myelinate sections of axons that are not myelinated. To date,
there have been no reports of direct conversion of somatic cells
into microglia. Further development of glial cell protocols will be
required to simulate non-cell autonomous neurological disease.
DIRECT CONVERSION MODELS OF
DISEASE
The diversity of conversion methods and sub-type specific fates
gives researchers considerable flexibility for modeling disease.
Disease states have been repeatedly shown not to impede
conversion into neurons. The use of iNs in studying disease is
still new and somewhat limited (Figure 2).
Amyotrophic Lateral Sclerosis
Lim et al. generated iNeurons via the inhibition of PTB method
to investigate three mutations in the nuclear localization signal
region of the gene Fused in Sarcoma (FUS), a causative ALS
gene (Lim et al., 2016). The ALS iNeurons showed increased
cytoplasmic FUS localization when compared to controls.
Another report studying mechanisms of mutant FUS generated
hiMNs converted from the fibroblasts of three ALS patients
with known FUS mutations. FUS was mislocalized into the
cytoplasm in all cases; however, only one of the three ALS
patients used in this study had a FUSmutation known to increase
cytoplasmic retention of FUS (Liu et al., 2016), emphasizing that
the use of patient-derived DC models aides in the discovery of
novel disease mechanisms. These FUS ALS hiMNs also showed
dramatically reduced electrical activity, failed to form functional
NMJs when co-cultured with primary mouse skeletal muscles,
had shrunken somas, and were more susceptible to cell death
when compared to controls. Control iMNs co-cultured with glia
from SOD1G93A mice undergo more cell death than those co-
cultured with control glia, replicating previously reported non-
cell autonomous effects (Son et al., 2011). Similarly, induced
NPCs from one patient with a SOD1A4V mutation and three
patients with the C9orf72 repeat expansion were differentiated
into iAstrocytes and were found to be toxic to co-cultured
primary mouse neurons (Meyer et al., 2014). iNs converted
from C9orf72 ALS patients by PTB inhibition showed RNA foci,
poly(GP) inclusions and poly(PR) inclusions (Su et al., 2014).
These reports suggest that DC models can replicate pathological
hallmarks of multiple ALS subtypes in ways similar to iPSC-
derived models.
Alzheimer’s Disease
CiNs from four Alzheimer’s disease patients with mutations in
APP (V717I) or PSEN1 (I167del, A434T, or S169del) showed
higher extracellular levels of Aβ40 and Aβ42 when compared
to controls. iNs from AD patients also showed an increase
in total tau and phosphorylated tau (Hu et al., 2015). Similar
results regarding extracellular levels of Aβ40 and Aβ42 have
been reported in induced NPCs differentiated into neurons from
three AD patients, one with APOE4/E4 mutation and two with
mutations in the PSEN1 gene (Hou et al., 2017).
Huntington’s Disease
Liu et al. (2014) investigated the use of induced neuron
technology to directly convert human fibroblasts from patients
with Huntington’s disease. Human fibroblasts from HD patients
were converted by inhibition of PTB (Liu et al., 2014). The HD
iNs exhibited nuclear mutant-Htt inclusions, abnormal neuritic
branching, and lower cell survival. In another study, iNPCs
were generated from HD patient fibroblasts and then further
differentiated into neurons which exhibited higher vulnerability
to DNA damage than controls (Hou et al., 2017).
Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) patient fibroblasts converted
into hiMNs saw reduction in neurite growth rate and, after 60
days in vitro, degeneration of the neurites (Zhang et al., 2017).
Induced neurons from patients with mutations in the PTEN-
induced putative kinase 1 (PINK1) pathway, a genetic risk factor
for Parkinson’s disease, show reduction of downstream targets of
this pathway which are involved in regulation of mitochondrial
quality control (Puschmann et al., 2017).
Direct conversion cells have demonstrated the ability tomimic
disease pathology and physiology in a number of neurological
disorders (Figure 2). What has not been established yet is
whether or not the retention of epigenetic signatures allows
DC models to recreate disease pathology more accurately than
rejuvenated iPSC models and whether cells generated from the
same patient using both differentiation methods would display
different disease phenotypes.
CONCLUDING REMARKS
Patient-derived CNS models have expanded rapidly in the past
decade. A variety of adult somatic cells can be reprogrammed
into iPSC’s and differentiated or directly converted into the cells
necessary to model disease, test novel drug candidates, and be
used for cell transplantations. As researchers today design new
studies of familial and sporadic neurological conditions, they
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must carefully consider whichmodel andmethodmost efficiently
answers their scientific question (Figure 3).
Patient-derived CNS models are time intensive. While direct
conversion decreases the time to generate neurons from somatic
sample collection due to the lack of reprogramming, the time
it takes to differentiate and mature functional neurons from
fibroblasts or iPSCs is similar. iPSC-based models offer more
efficient production of cells than direct conversion because cells
are infinitely expandable in both the iPSC stage and the NPC
stage. While the yield of the desired cell type (e.g., neuron
vs. astrocyte) is high, sub type (e.g., ChAT+ vs. CTIP2+)
yield can vary widely between different small molecule and
growth factor-based differentiation methods. Virally-expressed
transcription factors may increase specific cell subtype yield
in iPSC differentiations. While fibroblasts used for direct
conversion are infinitely expandable, the lack of an intermediate
progenitor stage creates a maximum one-to-one ratio of starting
fibroblasts to desired cell type. In addition, there are reports of
desired neuronal subtype yields of fewer than 10% (Vierbuchen
et al., 2010; Pfisterer et al., 2011). Given the time and expense of
generating the cells, this low yield must be weighed against the
scientific benefits of aging retention in the model.
One application for patient-derived cells which has not been
addressed at length in this review, but has been recently reviewed
byMarsh and Blurton-Jones (2017), Czarzasta et al. (2017),Wang
et al. (2017), and Smith et al. (2017), is the ability to implant
iPSC-derived or directly converted NPCs and differentiate them
in vivo to perform neurotrophic roles or replace cells lost through
degeneration.
While comparative analyses of epigenetics and gene
expression (particularly age-related genes) in iNeurons and
iPSNs have demonstrated the loss of aging signatures in
reprogramming (Mertens et al., 2015; Huh et al., 2016), the
effects of these expression changes on the ability to model disease
is poorly understood. Whether or not certain disease hallmarks,
including proteinopathies, morphological and functional
changes, and differences in survival in response to stressors will
manifest differently when epigenetic signatures are preserved
remains to be seen. A recent comparison of methylation of the
C9orf72 transcript in repeat expanded eSCs and iPSCs suggests
that toxic RNA transcription, and thus presumably RAN DPR
translation, is attenuated in iPSCs and may suppress the role
these mechanisms play in disease (Cohen-Hadad et al., 2016).
This supports the argument that reprogramming will have an
effect on disease pathology.
The clonal nature of iPSCs allows for the generation of
CRISPR-Cas9 correction of disease-causing mutations, which
can help establish whether certain pathologies observed in
the model are attributable to the mutation and provides an
isogenic control. This technique is not currently available in
direct conversion; however, there may be some advantage to
generating model neurons from a genetically and epigenetically
heterogeneous population of somatic cells rather than from
copies of a single iPSC clone, especially given the heterogeneity
of disease pathology between cells in patient tissue.
Both direct conversion and iPSC differentiation have
produced glia and several neuronal subtypes. Specific
differentiation methods, including transcription factor choice,
small molecule and growth factor choice, and plating methods
have been and will continue to be adjusted to create a higher
yield of desired cell types in less time. While, due to its earlier
discovery, iPSC differentiation technology is currently better
explored and developed, it is likely that iNeurons and other
direct conversion cell types will be equally fine-tuned in the near
FIGURE 3 | Key considerations for choosing iPSCs or DC to model neurological disease.
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future. With either method, care should be taken in regards to the
true identity of generated cell types, given the extensive cellular
conversion these cells undergo. Genetic and proteomic analyses
of differentiated or converted cell types, along with comparisons
to postmortem cell-type specific analyses, can address some of
these concerns.
The extensive reports of disease pathologies and pathogenesis
summarized in this review suggest that, despite the limitations
of in vitro human cell culture models, they are capable of
recreating disease-specific pathologies. In addition, new disease
pathways have been discovered using patient-derived cell culture
models which were then validated in postmortem patient tissue,
such as the presence of nucleocytoplasmic transport deficits and
nuclear pore dysfunction in ALS, FTD, HD and, likely, in other
neurodegenerative diseases. It is therefore likely that other novel
disease mechanisms will be revealed using these human cell
culture models.
Patient-derived cells offer hope for an endogenous, human
model of neurological disease, especially for sporadic cases which
cannot be modeled any other way, and provide a platform for
rapid therapeutic discoveries that are both personalized and
clinically translatable.
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